Ponencia presentada por el Dr. J. Raúl Moreno Gómez en el directo 'Controversias en tratamiento antitrombótico – Parte II', realizado el 6 de abril de 2021
Ponencia presentada por la Dra. Vanessa Roldán Schilling en el CardioTV· Live sobre 'Lo mejor en antitrombóticos' celebrado el 25 de noviembre de 2021.
Thrombolysis and thrombectomy for acute ischaemic strokeHan Naung Tun
Reperfusion by intravenous thrombolysis or endovascular
mechanical thrombectomy improves functional outcomes
after stroke, but benefit for both treatment modalities is highly
time-dependent. Maximum benefit requires minimisation
of onset-to-treatment times. The safety and efficacy of IV
rtPA is established across a broad range of clinical scenarios.
Endovascular treatment now offers greatly improved outcome
among patients with poor response to IV rtPA but efficacy
has been established only in the context of highly organised
neurovascular interventional services.
Ponencia presentada por la Dra. Vanessa Roldán Schilling en el CardioTV· Live sobre 'Lo mejor en antitrombóticos' celebrado el 25 de noviembre de 2021.
Thrombolysis and thrombectomy for acute ischaemic strokeHan Naung Tun
Reperfusion by intravenous thrombolysis or endovascular
mechanical thrombectomy improves functional outcomes
after stroke, but benefit for both treatment modalities is highly
time-dependent. Maximum benefit requires minimisation
of onset-to-treatment times. The safety and efficacy of IV
rtPA is established across a broad range of clinical scenarios.
Endovascular treatment now offers greatly improved outcome
among patients with poor response to IV rtPA but efficacy
has been established only in the context of highly organised
neurovascular interventional services.
La Dra. Silvia Valbuena López repasa los resultados del estudio con ticagrelor y prasugrel en pacientes con síndrome coronario agudo, presentado en ESC Congress 2019.
Lo mejor del ACC 2015 (San Diego)
Miércoles, 18/3/15 De 14:00 a 15:30
Casa del Corazón. Sociedad Española de Cardiología.
http://acc15.secardiologia.es/
Arritmias/Insuficiencia cardiaca
Dr. Romàn Freixa Pamias
Servicio de Cardiología. Hospital Moisés Broggi, Barcelona
Presentación "Análisis de coste efectividad con los nuevos antiagregantes. Causas de infra-utilización en España" del Dr. José Luis Ferreiro durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Estenosis aórtica riesgo moderado" del Lino Patricio durante la Mesa Redonda Hispano-Lusa sobre Controversias de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Novedades en el manejo del paciente con FA: actualización tras AHA 2016
22/11/2016 19:30h Casa del Corazón, Madrid
http://manejofa.secardiologia.es
#manejoFA
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria percutánea. Guías y preguntas abiertas
Dr. Antonio Fernández Ortiz, Hospital Universitario Clínico San Carlos (Madrid)
La Dra. Silvia Valbuena López repasa los resultados del estudio con ticagrelor y prasugrel en pacientes con síndrome coronario agudo, presentado en ESC Congress 2019.
Lo mejor del ACC 2015 (San Diego)
Miércoles, 18/3/15 De 14:00 a 15:30
Casa del Corazón. Sociedad Española de Cardiología.
http://acc15.secardiologia.es/
Arritmias/Insuficiencia cardiaca
Dr. Romàn Freixa Pamias
Servicio de Cardiología. Hospital Moisés Broggi, Barcelona
Presentación "Análisis de coste efectividad con los nuevos antiagregantes. Causas de infra-utilización en España" del Dr. José Luis Ferreiro durante la Mesa Redonda de Antiagregación de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Presentación "Estenosis aórtica riesgo moderado" del Lino Patricio durante la Mesa Redonda Hispano-Lusa sobre Controversias de la XXV Reunión Anual de la Sección de Hemodinámica y Cardiología Intervencionista (SHCI) de 2014 en Córdoba.
Novedades en el manejo del paciente con FA: actualización tras AHA 2016
22/11/2016 19:30h Casa del Corazón, Madrid
http://manejofa.secardiologia.es
#manejoFA
Pacientes con FA que sufren un SCA y son sometidos a intervención coronaria percutánea. Guías y preguntas abiertas
Dr. Antonio Fernández Ortiz, Hospital Universitario Clínico San Carlos (Madrid)
In patients with coronary artery disease (CAD), percutaneous coronary interventions (PCI) are the cornerstone of treatment for those presenting with an acute coronary syndrome (ACS); PCI has also been largely adopted in patients with chronic coronary syndromes (CCS).
Adjunctive pharmacotherapy, in particular antithrombotic therapy, has a pivotal role in optimising outcomes in patients undergoing PCI23. In fact, patients undergoing PCI may develop both acute and long-term ischaemic events.
Therefore, antithrombotic drugs, in particular antiplatelet agents, are key to the treatment and prevention of both local and systemic thrombotic complications.
Coronary artery bypass grafting with adjunctive
endarterectomy: A mandatory procedure in complex
revascularizations. current results and postoperative
considerations
Terapi Endovaskuler, Standar Baru Manajemen Stroke Iskemik Akut? Ersifa Fatimah
Konon, plenary pertama International Stroke Conference (ISC) 2015 yang digelar di Nashville, Tennessee bulan Februari lalu merupakan sesi ISC terseru selama beberapa tahun terakhir. Sebagaimana diberitakan dalam Medscape (Hughes, 2015), para presenter terpaksa memberi jeda beberapa saat untuk menyambut applause dari audiens. Suatu kejadian langka dalam partemuan saintifik. Adalah MR CLEAN, ESCAPE, EXTEND-IA, dan SWIFT PRIME yang menjadi topik hangat lantaran keempat studi ini dirilis dengan hasil yang positif dramatis hingga diprediksi bakal menjadikan terapi endovascular sebagai standar baru dalam manajemen stroke iskemik akut. Sehebat apakah 4 studi yang “menyejarah” dalam tatalaksana stroke iskemik akut ini? Bagaimana bila studi-studi ini diadopsi dan diaplikasikan dalam praktik sehari-hari di sentra kita?
Note: Esai ini ditulis saat SWIFT PRIME fulltext belum published (akhir Maret-awal April 2015). Update & beberapa revisi dibuat menjelang presentasi tanggal 18 Mei 2015.
Problem associated with drug eluting stentPRAVEEN GUPTA
This ppt will tell us about the problem which a cardiologist has to face after implantation of Drug eluting stent in a patient of coronary artery diseases. Although there are lots of problem but i am going to describe only three major problem.
Ponencia presentada por la Dra. Marisol Bravo Amaro en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del Corazón
Ponencia presentada por el Dr. Armando Oterino Manzanas en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del Corazón
Ponencia presentada por la Dra. Miriam Martín Toro en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del Corazón
Ponencia presentada por los Dres. M.ª Dolores Mesa Rubio, Javier Mora Robles, Margarita Reina Sánchez, M.ª José Castillo Moraga y José Luis Bianchi Llave en el CardioTV Focus, publicado el 25 de abril de 2024 en la Casa del Corazón (Madrid).
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
2. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
LIMITATIONS DURING PCI
• Peri-procedural thrombotic events.
• More and more complex coronary lesions (increased thrombotic
risk).
• A high proportion of patients are not optimally treated
• Increased proportion of patients with high bleeding risk (risk of
suboptimal ATT).
3. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
PERI-PROCEDURAL THROMBOTIC EVENTS
• 6,591 patients undergoing PCI for ACS in the ACUITY & HORIZONS-AMI trials.
• Intra-procedural thrombotic events in 7.7%.
Wessler JD, et al. Which Intraprocedural Thrombotic Events Impact Clinical Outcomes After Percutaneous Coronary Intervention in Acute Coronary Syndromes?:
A Pooled Analysis of the HORIZONS-AMI and ACUITY Trials. JACC Cardiovasc Interv 2016;9:331-337.
4. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
Adjusted HRs for IPTE and Its Components With 30-Day Outcomes
Wessler JD, et al. Which Intraprocedural Thrombotic Events Impact Clinical Outcomes After Percutaneous Coronary Intervention in Acute Coronary Syndromes?:
A Pooled Analysis of the HORIZONS-AMI and ACUITY Trials. JACC Cardiovasc Interv 2016;9:331-337.
5. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
Bortnick AE, et al. Five-year follow-up of patients treated for coronary artery disease in the face of an increasing burden of co-morbidity and disease complexity (from
the NHLBI Dynamic Registry). Am J Cardiol 2014;113:573-9.
Prevalence in the number of co-morbid conditions*
*Smoking, diabetes, renal insufficiency, peripheral arterial disease,
hypertension, hypercholesterolemia.
Prevalence in the no. of severe CAD characteristics*.
*Calcified stenoses, CTO, LMD ≥ 50%, type C lesions and/or 3-vessel
disease.
GROWING PATIENT AND LESION COMPLEXITY
6. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
LIMITATIONS OF PRE-LOADING
COAST: No benefit of preloading with prasugrel
Montalescot G et al., N Engl J Med 2013
ACCOAST
(Prasugrel in NSTEMI)
Montalescot G, et al. Pretreatment with prasugrel in non-ST-segment
elevation acute coronary síndromes. N Engl J Med 2013;369:999-1010.
Montalescot G, et al. Prehospital ticagrelor in ST-segment elevation
myocardial infarction. N Engl J Med. 2014;371:1016-27
ATLANTIC
(Ticagrelor in STEMI)
Figure S5. Major adverse cardiovascular events (death/MI/stroke/urgent revascularisation/definite
acute stent thrombosis) up to 30 days: Kaplan-Meier curves (mITT analysis set).
7. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
ADVANTAGES OF I.V. ANTIPLATELET DRUGS IN PCI
• More potent anti-platelet effect.
• Quicker effect.
• Not dependent on patient intake.
• Not dependent on gastro-intestinal
function.
• More homogeneous effect.
9. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
INDICATIONS OF IIB/IIIA INHIBITORS DURING PCI
1Neumann FJ, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87-165. 2Collet JP, et al. 2020 ESC Guidelines for the
management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2020 Aug 29;ehaa575. 3Ibañez B, et al. 2017
ESC Guidelines for the management of acute myocardial infarction in patients presentingwithST-segmentelevation. Eur Heart J 2018;39:119–177.
Stable CAD1
NSTEMI2
STEMI3
10. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
CANGRELOR: HOW CAN WE IDENTIFY THE BEST PATIENTS?
Steg PG, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-92
11. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
INTUBATED PATIENTS IN CARDIOGENIC SHOCK
Osmancik P, et al. A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter
Cardiovasc Interv 2010;75:158-66.
Reduced effect of clopidogrel
Comparison of the VASP (vasodilator‐stimulated phosphoprotein) index between patients with
hemodynamically complicated and uncomplicated AMI
12. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
Steg PG, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-92
CANGRELOR: HOW CAN WE IDENTIFY THE BEST PATIENTS?
Events: death, MI, ischaemia-driven revascularisation, or stent thrombosis at 48 h
13. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
Steg PG, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981-92
Events: death, MI, ischaemia-driven revascularisation, or stent thrombosis at 48 h
14. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
CANGRELOR: PATIENTS WITH ACS VS STABLE CAD
Abtan J, et al. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing
Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. JACC: Cardiovasc Interv 2016;9:1905-13.
15. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
CANGRELOR: PATIENTS WITH ACS VS STABLE CAD
Genereux G, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial
Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol 2014;63:619–29
16. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
THE IMPORTANCE OF LESION COMPLEXITY
Stone GW, et al. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition
after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. Eur Heart J 2018;39:4112-4121.
Angiographic complexity and benefit of cangrelor
(13,418 lesions in 10,854 patients from CHAMPION PHOENIX).
CHAMPION PHOENIX Angiographic Analysis
Number of High-Risk Angiographic Risk Factors
Stone GW, Genereux P, Harrington RA, et al…. Bhatt DL. EHJ 2018.
ARR 1.5 ARR 0.6 ARR 0.9 ARR 2.3
• Bifurcation.
• Left main.
• Thrombus.
• Angulated.
• Tortuous.
• Eccentric.
• Calcified.
• Long.
• Multi-lesion.
25% of patients
Number of high-risk PCI
characteristics
17. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
THE IMPORTANCE OF LESION COMPLEXITY
Stone GW, et al. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition
after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. Eur Heart J 2018;39:4112-4121.
ARR 1.6
ARR 3.1
Number of high-risk PCI
characteristics
18. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
THE IMPORTANCE OF LESION COMPLEXITY
Stone GW, et al. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition
after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. Eur Heart J 2018;39:4112-4121.
19. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
“Despite these important considerations, there are several clinical situations where cangrelor could have a major
role. First, because cangrelor is administered intravenously and has rapid onset, it could offer particular
advantages in the STEMI primary PCI setting, especially in patients at high risk, in those experiencing nausea and
vomiting, or in those who are intubated or in cardiogenic shock. There is little opportunity for pretreatment in this
setting and there is invariably a delay to optimum platelet inhibition with even the most effective oral agents. A
randomised trial of cangrelor versus placebo on top of optimum dual oral antiplatelet therapy, including either
ticagrelor or prasugrel, would help solidify its role in this setting. Second, because patients with high-risk non-
STEMI (GRACE score >140) preferentially benefit from early intervention, cangrelor, with its rapid onset and
offset, might offer an advantage in this population. Third, in centres where pretreatment is not routine clinical
practice, cangrelor will probably become a preferred option. Fourth, cangrelor is an attractive option in patients
with high-risk anatomic or clinical features undergoing same-sitting or ad hoc elective PCI for stable coronary
artery disease. There is little opportunity to benefit from preloading in these patients and, somewhat surprisingly,
neither ticagrelor nor prasugrel has been formally studied in this large group of patients”.
Mehta SR, et al. Cangrelor: a new CHAMPION for percutaneous coronary intervention. Lancet 2013;382:1961-2.
20. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
1Rossini R, et al. Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience. TH Open. 2020;4:e437-e445. 2Delvoye
F, et al. Antiplatelet Therapy During Emergent Extracranial Internal Carotid Artery Stenting: Comparison of Three Intravenous Antiplatelet Perioperative Strategies. J Stroke Cerebrovasc Dis.
2021;30:105521. 3Cortez GM, et al. The use of cangrelor in neurovascular interventions: a multicenter experience. Neuroradiology. 2020 Nov 11. 4Cervo A, Ferrari F, Barchetti G, Quilici L, Piano M,
Boccardi E, Pero G. Use of Cangrelor in Cervical and Intracranial Stenting for the Treatment of Acute Ischemic Stroke: A "Real Life" Single-Center Experience. AJNR Am J Neuroradiol. 2020;41:2094-
2099. 5Linfante I, Ravipati K, Starosciak AK, et al. Intravenous cangrelor and oral ticagrelor as an alternative to clopidogrel in acute intervention. J Neurointerv Surg. 2021;13:30-32. 6Fahnhorst SE, et al.
Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices. Artif Organs. 2021;45:38-45. 7Vargas D, et al. Cangrelor PK/PD analysis in post-operative neonatal
cardiac patients at risk for thrombosis. J Thromb Haemost. 2021;19:202-211.
• Bridging therapy for surgery after coronary stenting1.
• Neurovascular interventions2-5.
• Pediatric patients supported under ventricular assist device6.
• Neonates at high risk of thrombosis7.
INDICATIONS OF CANGRELOR OUTSIDE OF PCI FIELD
21. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
SWITCHING FROM ORAL AGENTS TO CANGRELOR
Expert Consensus Recommendations on Switching
Bridging from oral to intravenous P2Y12 inhibitors
• For both cardiac and noncardiac surgery, if withdrawal of P2Y12 inhibiting therapy is needed, clopidogrel and
ticagrelor should be discontinued for 5 days and prasugrel for 7 days.
Angiolillo DJ, et al. International Expert Consensus on Switching Platelet P2Y 12 Receptor-Inhibiting Therapies. Circulation 2017;136:1955-1975.
22. Antiagregantes endovenosos, ¿cuándo usarlos? J. Raúl Moreno Gómez
CONCLUSIONS
• The use of IIb/IIIa inhibitors should be restricted to bail-out or
procedural complications (intra-procedural thrombotic events).
• Cangrelor prevents peri-procedural thrombotic events both in
patients with ACS and stable CAD.
• Lesion complexity plays a key role for selecting patients candidates
to receive cangrelor.
• Other indications of cangrelor include bridging therapy for surgery
after coronary stenting.